Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

[cafead]

via Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

article source